Advances in molecular oncology have transformed how clinicians approach lung cancer, making genetic profiling a cornerstone of treatment planning. Understanding the role of MET mutation and non-small cell lung cancer is essential for patients, caregivers, and healthcare providers navigating today’s rapidly evolving therapeutic landscape.
Key Takeaways
- MET gene mutations, particularly MET exon 14 skipping, are actionable drivers found in approximately 3–4% of non-small cell lung cancer cases.
- MET amplification is a distinct alteration that can arise as a primary event or develop as a resistance mechanism to other targeted therapies.
- FDA-approved MET inhibitors such as capmatinib and tepotinib offer meaningful response rates in patients with MET exon 14 skipping mutations.
- Prognosis for MET-positive NSCLC varies by alteration type, but targeted therapy has meaningfully improved outcomes compared to chemotherapy alone.
- Ongoing clinical trials continue to explore novel MET-targeted agents and combination strategies to overcome resistance and improve survival.
What Is MET Mutation in Non-Small Cell Lung Cancer (NSCLC)?
The MET gene encodes the hepatocyte growth factor receptor (HGFR), a protein that plays a critical role in regulating cell growth, survival, and migration. Under normal physiological conditions, MET signaling is tightly controlled. However, when the gene undergoes certain mutations or alterations, this regulation breaks down, leading to uncontrolled cellular proliferation — a hallmark of cancer. In the context of lung cancer, MET alterations function as oncogenic drivers, meaning they can independently fuel tumor development and progression.
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer diagnoses worldwide, according to the American Cancer Society. Within this broad category, a subset of patients harbor MET-specific alterations that make their tumors distinct from those driven by other well-known mutations such as EGFR or ALK. Identifying these alterations through comprehensive molecular testing — including next-generation sequencing (NGS) — has become a standard practice in advanced NSCLC management, as the mutation type directly informs treatment selection.
MET alterations in NSCLC generally fall into three categories: point mutations, exon 14 skipping mutations, and gene amplification. Each type affects the MET pathway differently, carries distinct clinical implications, and may respond to different therapeutic approaches. Because symptoms and imaging findings alone cannot distinguish MET-altered NSCLC from other subtypes, molecular profiling is indispensable at diagnosis and, in many cases, at disease progression.
MET Exon 14 Skipping and MET Amplification: Key Alterations in NSCLC
MET exon 14 skipping lung cancer refers to a genomic alteration in which mutations near the splice sites flanking exon 14 of the MET gene cause that exon to be excluded during messenger RNA processing. Exon 14 encodes a region containing a ubiquitin ligase binding site responsible for degrading the MET receptor. When this region is skipped, MET protein degradation is impaired, leading to sustained and abnormally high MET signaling. This alteration is detected in approximately 3–4% of NSCLC cases and is more prevalent in older patients and those with adenocarcinoma histology.
MET amplification NSCLC is a separate and mechanistically distinct alteration. It refers to an increase in the copy number of the MET gene, which results in an overabundance of MET protein and hyperactivation of downstream signaling pathways. MET amplification can occur as a primary (de novo) event present at initial diagnosis, or it can emerge as a secondary resistance mechanism — most notably in EGFR-mutated NSCLC patients who develop resistance to EGFR tyrosine kinase inhibitors (TKIs). Studies suggest that secondary MET amplification accounts for resistance in roughly 5–20% of patients following EGFR TKI treatment, underscoring the importance of repeat molecular testing at progression.
It is important to distinguish between high-level and low-level MET amplification, as clinical significance and therapeutic response can differ substantially. High-level amplification (gene copy number ≥ 10 or MET/CEP7 ratio ≥ 5) is generally associated with stronger dependence on MET signaling and greater likelihood of responding to MET-targeted therapy. Accurate detection requires standardized testing methodologies, including fluorescence in situ hybridization (FISH) and NGS-based platforms, and results should be interpreted within a multidisciplinary team setting.
Targeted Therapy Options for MET Mutation and Non-Small Cell Lung Cancer
MET gene mutation in NSCLC treatment has advanced considerably with the development and regulatory approval of selective MET tyrosine kinase inhibitors. Two agents — capmatinib (Tabrecta) and tepotinib (Tepmetko) — have received FDA approval specifically for adult patients with metastatic NSCLC whose tumors harbor MET exon 14 skipping mutations. Both drugs work by binding to the ATP-binding site of the MET receptor, thereby blocking its kinase activity and interrupting downstream proliferative signaling.
Clinical trial data supporting these approvals demonstrate meaningful efficacy. In the GEOMETRY mono-1 trial, capmatinib produced an overall response rate (ORR) of approximately 68% in treatment-naive patients with MET exon 14 skipping mutations, with a median duration of response exceeding 12 months. Tepotinib demonstrated a similar ORR of around 46% across previously treated and untreated patients in the VISION trial, with responses that were durable and consistent across subgroups. These outcomes compare favorably to traditional platinum-based chemotherapy, which typically yields ORRs of 25–35% in unselected NSCLC populations.
Beyond exon 14 skipping, MET-targeted agents are also being evaluated in the setting of MET amplification, though regulatory approval in this context remains more limited. Combination strategies — such as pairing a MET inhibitor with an EGFR TKI in patients with co-occurring EGFR mutations — are under active investigation. Additionally, savolitinib and crizotinib, while not exclusively MET-focused, have demonstrated activity against MET-altered tumors in clinical studies. The choice of therapy depends on mutation type, prior treatment history, and the presence of co-occurring genomic alterations.
| Drug | MET Alteration Targeted | FDA Approval Status | Notable Trial |
|---|---|---|---|
| Capmatinib (Tabrecta) | MET Exon 14 Skipping | Approved (2020) | GEOMETRY mono-1 |
| Tepotinib (Tepmetko) | MET Exon 14 Skipping | Approved (2021) | VISION |
| Crizotinib | MET Amplification / Exon 14 | Off-label / Investigational | Multiple phase II studies |
| Savolitinib | MET Exon 14 Skipping / Amplification | Investigational | SAVOIR, SAFFRON |
Prognosis and Clinical Trials for MET-Positive Non-Small Cell Lung Cancer
MET positive non-small cell lung cancer prognosis depends on several intersecting factors, including the specific type of MET alteration, disease stage at diagnosis, performance status, and access to targeted therapy. Historically, MET exon 14 skipping mutations were associated with an older patient demographic and a prognosis that lagged behind other driver-mutated NSCLC subtypes. However, the introduction of selective MET inhibitors has substantially changed this outlook. Patients with exon 14 skipping mutations who receive approved targeted therapy now demonstrate median progression-free survival in the range of 9–12 months, which represents a marked improvement over historical chemotherapy benchmarks.
MET amplification, particularly when it arises as a resistance mechanism following EGFR-targeted therapy, often signals a more challenging clinical scenario. In these cases, the tumor has already demonstrated the capacity to adapt, and therapeutic options may be more limited. Nonetheless, emerging data from studies evaluating combination regimens — such as a MET inhibitor added to an EGFR TKI — suggest that disease control is achievable for a meaningful proportion of patients even in this setting. The durability of responses remains a key area of investigation.
MET mutation lung cancer clinical trials represent one of the most active areas of oncology research. Ongoing and recently completed studies are exploring several important questions, including the optimal sequencing of MET-targeted agents, strategies to overcome acquired resistance to first-generation MET inhibitors, and the role of MET-directed therapy in earlier disease stages such as adjuvant or neoadjuvant settings. Bispecific antibodies and antibody-drug conjugates targeting MET are also entering early-phase evaluation.
Patients with MET-altered NSCLC are strongly encouraged to discuss clinical trial eligibility with their oncology team. Trial participation not only provides access to investigational agents before widespread approval but also contributes to the scientific knowledge base that will benefit future patients. Resources such as ClinicalTrials.gov and oncology-focused patient support organizations can help identify relevant studies based on mutation profile, prior treatment history, and geographic location.
- Molecular testing at diagnosis and at disease progression is essential for guiding MET-specific treatment decisions.
- MET exon 14 skipping mutations are the most therapeutically actionable MET alterations in NSCLC today.
- Resistance to MET inhibitors can develop through secondary MET mutations or activation of bypass signaling pathways.
- Clinical trial enrollment offers patients access to next-generation MET-targeted agents and combination therapies.
- Multidisciplinary care teams — including medical oncologists, molecular pathologists, and genetic counselors — are key to optimizing outcomes in MET-positive NSCLC.
Frequently Asked Questions
How common are MET alterations in NSCLC patients?
MET exon 14 skipping mutations occur in approximately 3–4% of NSCLC cases, while MET amplification is present in a broader range of patients depending on how it is measured and whether it arises as a primary or secondary event. Because these percentages translate to thousands of patients annually given the overall burden of lung cancer, routine molecular testing is recommended for all patients with advanced NSCLC to identify those who may benefit from MET-targeted therapy.
Can MET-targeted therapy be combined with immunotherapy or chemotherapy?
Combination strategies are under active investigation. Some trials are evaluating MET inhibitors alongside immune checkpoint inhibitors or chemotherapy to determine whether synergistic benefit is achievable. Early data show variable results, and tolerability is an important consideration. At present, MET inhibitor monotherapy remains the standard approach for patients with confirmed MET exon 14 skipping mutations, while combination regimens are generally reserved for clinical trial settings or carefully selected cases managed by experienced oncologists.
What happens when a patient develops resistance to a MET inhibitor?
Resistance to MET inhibitors can develop through several mechanisms, including secondary mutations within the MET kinase domain, bypass pathway activation through EGFR or RAS signaling, and MET amplification on a background of other alterations. When resistance occurs, repeat molecular profiling — ideally through liquid biopsy or tissue re-biopsy — is recommended to identify the specific resistance mechanism. Next-generation MET inhibitors with activity against resistance mutations are in development and accessible through clinical trials.
